Aurinia Pharmaceuticals (AUPH) 4 May 232023 Q1 Earnings call transcript

Greetings, and welcome to Aurinia Pharmaceuticals Inc.

First Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions].

conference recorded. this reminder, a is being As

I to Relations your like to for conference over turn the host, Pharmaceuticals. you. would Thank now Aurinia Jamie Harrell, Investor

You may begin.

and thanks quarter first financial results joining operator, discuss highlights. XXXX everyone operational you, review and and today's Thank call webcast and to Aurinia's for

morning on our Officer. Chief this Greenleaf, Executive are me Joining call Officer; Chief Financial Peter the and Miller, Joe

issued first results Aurinia morning, and quarter a the highlights for announcing financial This press its operational XXXX. release

filed financial statements company XX-Q. its Form the addition, In quarterly on

For please Securities site information, on are refer more with to Web the and also Aurinia's U.S. at Aurinia's which filings auriniapharma.com. Exchange Commission, available

uncertainties, During statements are and based may this differ forward-looking forward-looking number statements may subject These call, make on to current and of actual materially. Aurinia results expectations. a risks significant

that to statements time. as Canadian and Please obligation no note such required based law, that and any noted unless statements. Form May the currently are X, of For in disclosures Securities Commission this statements Form U.S. along all securities annual press future and affect could and XXXX, refer Exchange otherwise call XX-K, made please during information are Aurinia discussions to assumes on upon us current authorities. at as Aurinia's available of and today's quarterly businesses, today, the its the by filings financial with Except factors on the release and Aurinia's report to XX-Q recent results with update

Now, Aurinia's and let President CEO, Peter me turn Greenleaf. Peter? call the to over

the our results. excited progress the call. financial first It's three quarter, to solid all with I through to months on execution you we'll you today's company's primarily the joining morning, company this XXXX, to for first us start everyone. good focus on morning. a and share want commercial Jamie, LUPKYNIS' our and we're and year of Thanks, Today, been thank

team efforts on. focused been activities We will for that the performance alongside information executing indicators commercial, We'll trajectory additional and from results. through call updates the turn we initiatives development on recently Joe group outline financial provide to will our believe launched walk U.S. our then world. brand commercial the in the financial impact key and medical I'll our regulatory Miller around the details you that we've and from over our further to in

with of story share So quarter seen to is short quarter significant number get to new six let's over last product performance, terms the shipped. started net our hit on the our and we that patients wallets therapy best number of business we've date revenue, first I'm progress and months. XXXX pleased that in of

progress We have property regulatory and fronts. intellectual also made significant clinical, LUPKYNIS on

factors XX.X XX% XX% were and for we several performance over of compared the to. the XXXX. prior that quarter There revenues million product are to this QX attribute year, quarter, fourth the Net up

fourth quarter strong in quarter XXX. first, levels began form December PSF quarter, over productivity and of the PSFs strong highest patient ended The XX% of This ramp the that the increase ever in a year. start We first last our represents our at building approaching off XXXX. with November

As we to our XXX an April PSFs. of XXX bringing additional XX, added PSFs XXXX, total year-to-date

the Second, of insurance part to as early helped and mitigate our QX team's year XXXX worked patients year-over-year to in transitions. execution QX 'XX through impact new the normal plan

patient patients teams to practices quarter, therapy. our impact attempt To first towards care for on As copay support process, negative a of can insurance maintain this, the we continuity the and in order discussed, previously to help and changeover in services have proactively consistent resets policy counter changes deployed patients.

on a and we disruption overall less believe it our a positive impact of result to As efforts, our patients, had saw results. we our

screening and continue commercial In educating therapy. proper and on of differentiation our identifications LUPKYNIS through benefit would from importance clinical positive of most impact activities focus who patients the see to our physicians addition, on

clinical LUPKYNIS care provider this interactions, especially face-to-face enabled the working, activity is and healthcare differentiating focusing we tier with Our standard message on of current believe top the data from These physicians, nephritis strong gain study, our traction in sensitive call real coupled three-year difference. powerful making AURORA with promotionally the the market. to from lupus are a us has extension pivotal efforts,

quickly our Just in the calls launch. as highest we this. to new have therapy. PSF, PSF the month to a since we our prescribers add the In on month once since convert quarter, Obviously, with we in highest a of a small And day to we tactical how launch. and repeat a we that patient example per first of March, convert we closed had number and measure percentage

access several to therapy. to past edits and closely prior them to patient by help meaningful the removing there office This PBMs continue LUPKYNIS. staff working to patients we and step the accomplished formulary been quarters, with physicians, making improve and with and conversion to major barriers, strides payers out their the has Over authorizations

to period, that of and being we've conversion of less. this than getting time progress XX% reducing to on the fronts. patients' forms rates, During to year, converting up Even patients in a drug. both with the on rate our is remained of quarter improvements to XX% therapy progress is prior to on made on more first meaningful on drug on or strong, in patients patients This therapy conversion XX average approximately start with converted XX% average from significant very PSF importantly, more days

XX% first XX is three-year the prescribing study remain the quarter patients We months. from and At also clinical behavior an data the having XXXX, therapy of patient persistency. on impact after AURORA of extension believe on end the

retention. remain pleased the this now across on remain period We continues of to grow. out number XX February to patients as patient that XX patients months. therapy to see we patients therapy In time XX% of level of reported see of are at We months, XX% on

are about on through we've while at through of patients that a seen therapy it XX% And remaining only therapy, of time. months looks number small XX

which with X,XXX year, prior is of have This XX XXXX. total first consistent over treatment to day, remains quarter a So on patients and XX% increase represents the per therapy. tablets patients March stable of now to XX%. to XX% at reasonably of we about prior dosing periods, an periods of regimen, adhering Through this

recap, all improvements our major commercial in sales to by So driven in areas. was performance QX

teams' execution and field, the commercial on momentum. Our importance treating drive therapy to healthcare educating the patients in maintaining screening, practitioners on continues of

conversion, to for from million. primarily conversion and to persistency on revenue Based our based everything This current million XXX rates, regarding XXXX our on XXX start of increasing well consistent as maintaining and time guidance XXX product rates range just I've prescription million assumptions net discussed, we're forms, XXX million to guidance as pricing. is speed

In seasonality impact seen the that also last of the addition, it includes years. potential two summer we've

further impact drive LUPKYNIS our kicked off top and imperatives nephritis. around we initiatives strategic two commercial Recently, that lupus and new

the as XX taken first I original this know further study, AURORA The includes our To strengthen data announced of clinical recently out extension obviously the we Biopsy of was, and course, this was of both Renal AURORA you from which clinical study critical. LUPKYNIS taken program, differentiation top the story, AURORA Sub-study think study distinguishing segment months first was generation out therapy. all our and from CNIs, line of -- study

MMF are or demonstrating of believe months. further kidney further stable and East generation nephrotoxicity low-dose meeting. from first XX differentiate that of of at not these arm Clinical active And chronicity data showed patients similar Congress this Rheumatology demonstrated will control at These meaning any the We presented alone, be data the scores region worsening this steroids improvement patients histologic LUPKYNIS-treated inhibitors. LUPKYNIS week function to with activity calcineurin

by treatment get The about monitoring second area to and more was uncomfortable patients their the need reinforce to and get engaging with healthcare screening, practitioners for educating engaged care. routine their and

role their understand we play the actually own disease a On urine patient screening and seek major and believe out the need in they management informed patient front, treatment. routine they can an when

singer lupus strategic to most may has of website. spokesperson thousands Get hundreds Since recent Many nephritis. is Braxton, prioritize who specialist a that announcement nephritis of lupus October with Toni mix winning since Uncomfortable has of launch in kidney been area Get high you their million health. our social complete campaign impressions of nearly the Grammy the patients has its a campaign. XXXX, component their marketing Award across performing Aurinia's their This Uncomfortable activate living new been have visits lupus find is for XXXX, where to of in It and routine discuss testing XX with to media can patients management of the to generated digital and seen

website media, new of online visits This and days. articles, engagement an the In outreach five on and people, in over target course, days have Uncomfortable reached nearly which our has reach just XXX XX television Get audience Toni of spokesperson, as the appearances social launching the that we audience. pull-through XX,XXX is, just has million created Braxton generated first website of three

the strengthen in intellectual corticosteroids, our patent from LUPKYNIS to method We're use issued this eGFR and as used Office AURORA the a an The further would briefly patent protection method to the to and with for using to a XXX, issued Orange recent patent to XXXX. This I proprietary property, now in reflecting the combination refines No. in X further newly patent, Moving our the AURORA provide product like of both additional to new highlight with method the LUPKYNIS Patent list Book. working dosing of and in patent unique and layer dosing progress using has regimen, lupus U.S. position. trial. patients Patent extension MMF potential dosing nephritis of pharmacodynamically of up LUPKYNIS currently

partnership Closing LUPKYNIS, momentum out the U.S. significant with for our effort launch Otsuka resulted globalization our has with this outside in year.

UK body can MMF in NICE, yesterday, agency with The the that announced will As be available soon nephritis. combination recommendation issued lupus LUPKYNIS patients just guidance value-based across LUPKYNIS and treat for to issued used with a United Kingdom. UK's healthcare, reimbursement entire the be their governing

million a upon second these in We pricing The currently reimbursement pending further support EU half approval Japanese And globalization of half of for would the eligible milestone. and reminder, company be our as an PMDA XXXX. submission for countries, $XX European towards major Japan, approvals market we a five are efforts LUPKYNIS. of the anticipate XXXX. the approval additional working of In our and second submission in the three combination

call return open for turn the more our any questions a Joe review for to might for financial the that the like Joe? end line to now recap, over I'd call you then up detailed a So and results. quick the have. of I'll at of

everyone. good and morning, Peter, you, Thank

short-term continued to post As had investment approval cash compared The cash in in commitments to and million cash, restricted December at and XX, equivalents, restricted cash of XXX.X equivalents, primarily related investments million of XXXX. and we drug LUPKYNIS. the our cash, activities XX, is decrease March of cash XXXX, commercialization investments XXX.X approved

funding receipts cash resources in in Inventory including of We FDA-related our sales packaging for of years. commercial have infrastructure, manufacturing, from partially offset and activities, research post and funding advancement next by increase commitments, our supply, approval obligations our current sufficient purchases funding commercial the advancing capital pipeline, our commercial to we supporting include which financial that development of our fund working LUPKYNIS. an least drug believe few programs, at operations, and

take therapy results a our for let's net to period. revenue The quarter for the by into first increase as for year-over-year. in minutes million increase revenue financial penetration driven regarding on is LUPKYNIS, few Now, year from and to first product in patients to Total further net an in the market XX.X customers go by main evidenced quarter detail compared prior increased XXXX. our the XX% of primarily LN two the predominantly due increase

patient net LUPKYNIS as But expect approaching per more persistency, annualized figure basis. XX,XXX for than per remains continue as dosing on patient payer stay evolve. over per mix guidance as initial on previously, on our quarterly and this of go a on per revenue higher patients revenue realizable therapy we to we year realizable basis, time, discussed [ph] Net and and patient an

since quarter the analyzed number initial estimate. ranged Every closer our has and launch, closer this to

XXXX XX Total As operating the is million and dose respectively. sales persistency. of XXXX biggest first million, we've XX.X our driver and said in the cost the of for were adjusting estimate of and expenses this past, and quarters

and further product-related give XXXX as and periods. drivers The expenses, XXXX Let an due of was of of approximately a breakdown respectively. quarters for increase sales both for margin the primarily gross XXXX, for me first was XXX,XXX to fluctuations. in was XXXX first and now and Cost revenue, XX% operating increase XXX,XXX of the quarters

compensation compared share-based to ended primary three of first in related months and ended for XXXX inclusive million as X Selling, general XXXX XX.X non-cash quarters XXXX the X.X administrative XX.X compensation and marketing and SG&A SG&A were share-based share-based fees of XXXX million pharmacovigilance, costs. and respectively. expenses, for first was the XXXX, compensation, services XX, March of and XX, professional Non-cash an drivers related the the XXXX, for and the increase travel expense March respectively. were quarters same for increase in and million and to million expense The expense period and

expense to the in a of contract advancement related Research compensation, XXXX. partially and due share-based and to the The commitments FDA quarters was offset increase further the salaries, primary post AURORA and for and the in were increase non-cash increase for development expenses, XX.X inclusive XX.X were of to by AURXXX million XXXX. costs million completion decrease of X of XXXX LUPKYNIS. the share-based AURXXX, study The compensation continuation and research first approval the employee in for benefits an drivers organization

expense rates. first million compensation first was respectively. The income was XX, period. of the was and a for XXXX share-based March of for in investment, XXXX, yields and million prior our for X.X quarter due X the year to XXXX result interest quarters versus million rising increase XXX,XXX X.X the higher R&D Interest ended Non-cash mainly

of Aurinia loss prior common per of share $X.XX per million, loss recorded first common share, compared net loss XX.X $X.XX loss quarter first the a of XXXX, net XX.X For year to or the for net million, quarter. a or net

within recently to Before performance the undertook. like business such and its emissions, our their you as diversity, back and that turning learn topics, topics. management, affordability, among engagement, a recently which provides for to and engagement, and energy our priorities, ethics, the we community closing ESG Aurinia's highlights call pleased ESG first initiative comments, corporate To access chain to website. supply of section retention, to and within other look baseline about IR report, priority I'd management more and and share figures company's on patient employee please talent Aurinia I'm inclusion update equity Peter corporate ESG some published the approach

With like hand that, some Peter call closing the to for Peter? I'd over back remarks. to

Joe. Thanks,

throughout remain in patients We driving the thank call, the delivering all-time look and keeping excited want to need, in quarter, heard for the results I again many business. first about we're the us posted on globally. call highs to U.S. today. to focused As the strong on across obviously you LUPKYNIS joining forward way. the everyone and along you for results our hitting We

We'll now questions for might open any you the have. Operator? call

the Brayer floor take questions. Cantor first gentlemen, now is for and Ladies Instructions]. Olivia. [Operator ahead, you. Thank from Please open And our we'll question Olivia go from Fitzgerald.

Good MKT pre-op whether I'm a Thank for is commercial questions, from, seeing better impact guys the biggest where get congrats Hi. this so print. and for trying year the the came the letter just prescribers acceleration more changes far on nice come can coming some around from to out recent if other you new are prior strategic that in review see U.S.? the growth it's tailwind positive or from actually letter morning. the sense had you any any Where requirement and to Thanks, starting contact comments online? them address Have guys Capital? the with a process broadly? you then guys. or you're And you

Thanks, Olivia. with commercial start first. And me question let the

for PSFs. As great from for in across call, many think everything they're having the we all-time right, highs, quarter said experienced drivers and us, the all a I board we

year. that and in transition through the think impact in well. PSFs sure of insurance retention affect the that patients their continuity knock and early impact processes had year, last and the way year. -- et we end sort we they their the impact we our at So to the making ease as as likely be of better the work real working next think them care all office We those on and having an enter if is cetera, in going did with I the and patients get mix the on And staff the had marketing most is year effect with But quarter January, physicians of whole felt the quarter. patient

So as one I on metric major driver. to can't a really plug it

I the getting our On us and have your us several appear those in impacted in be therapy. continue being second offered. years. few we any these we have hasty and no across And think And efforts, the are on fronts. it's clear. for times team meetings They board. pressure on despite that. and biggest value-enhancing coming best those Directors intend Board to on and on therapy the to a think Capital what sell and new MKT crystal of do patients impacts Members And on at resulted staying to been two to the it me public process and patients management Obviously, company therapy question, let quarter, met be last have all I just price. instead unproductive ideas appear with have of in pursue the the would

results I played long near value delivering show, has As our is term. significant seeing. for unlock current to an think our further we're and the momentum in positioning And us results, term shareholders, role strategy today's integral Board

vote that Olivia, as both directors. So to ignoring seems you've to campaign. And to facts MKT we're to this. eight we're announce, they recommended of be The Glass seen, incumbent ISS engaged pleased Lewis with understand and disappointed we've a have shareholders these reelect and launching point, and this up all that distracting shareholders our

of out, directors, shareholders. looking have that transactions. their would in And seven on our to experience. all value-creating acquired opportunities. to to been and/or successful clear, been the value tenures backgrounds The of continues creating this And Board the companies focus sort by Board think of of just members in now So value-enhancing out involved of know directors I several have open as our M&A any is for have most Board management be eight round during and the to the at

So for I question. this be you interactions on during but we won't our the investor commenting call, with further thank the

Thank you. Excellent.

our ahead, take question next Maury. from we'll And Please from go Maury Jefferies. Raycroft

Hi. MKT Good for the morning. is for Capital This Farzin issue. clarifying on Maury. Thanks on

to ask I So wanted on guidance. the you

is of XXXX benefit then the there. X version LUPKYNIS the out and [indiscernible] draft class. AURORA KDIGO data So the a with saw we guidelines, But profile and the risk X that we as saw grouped

LUPKYNIS' whether So on is the is, further will clarify anything there data differentiated wanted profile? remain the in the works address or to to as based guidance

Yes.

work guidelines these KDIGO know, you the physician take as derived first to bodies driven and also the other think years to redraft. and ACR, And [indiscernible] months So they to bodies into some guidelines the totality are pass are large that ASN guidelines practice are by believe, Understand all are on. and in guidelines ACR continue take but I in from -- usually, the there rheumatology. I that referenced guidelines, and published we governing ones out something they by think all nephrology cases these Yes, our evidence don't of these account. ASN, and KDIGO, I literature. there, and

things has most that recently don't take AURORA or been not published issued account data the like or most into -- they recently data So extension, published.

use. which terms So is next itself to position I first-line, really drug see to data results. inhibitor. into we sell it a be therapy, us we have feel against We as position the utilize of we and studied over can for in speaks a to CNI it, of as generation the very group to first we sell second-line inhibitor. of data alongside as And a in continue broad the patients, think think calcineurin data product us confident a these the a calcineurin generation that a a our where both And puts see will don't time, historical that We able evolve.

of there how that progress out wasn't we'll forward totality So but evidence of in know continuing probably to guidelines out to do there, there. they the look the or our guidelines, nature because that's

We have some work to do.

see B cell the quick sense. the LUPKYNIS more that future, where what like failed use, in just follow [indiscernible] are like some patients? Make a is Benlysta-treated increased or you And then up therapy areas in patients, prior patients of

dose believe B seen there's the not majority treatment B and our I It's in to MMF would of experienced lupus, today treatment lupus cell think, first. treated of first. And those the we treatment as will want nephritis I course that a question, therapies have of in treatment our cell will are available not patients for a in therapy a patients get of and as earlier cell goal experience I by with more therapy combination in more progressive B have say is majority that good steroids and the these do LUPKYNIS cycle. MMF underscore low The seen with have I of steroids. patients that patients treated to being lupus. cell But therapy that become B patients,

treated Saphnelo us, if with patients Benlysta a sustained like then are more for they it we lower when for they not treatment course of lupus newly are consider therapies approved obviously and time. of a therapies it's nephritis, for the much products So lupus more aggressive before the treatment more competitive but positioning and that see get positive rapidly nephritis ours as proteinuria over approved and of lupus. are And that

a we assume patients in that marketplace the seen new time, course lupus. of B for So cell be having natural therapies just would of progression will over therapies

so you Thank much.

go Cowen. comes question And you. TD Ku Stacy. from Please Stacy from our ahead, next Thank

Hi, the there. performance. on congratulations strong and our Thanks for taking questions

patents, then the on additional question. first be examiners the you you the is patent term patents XXX So potential going we on any provide We actually different or importance? trajectory. quarterly extension but And matter subtleties would your LUPKYNIS, and regarding composition progress first can is can that's did patent an XXXX, to on October moats, that have XXX, to on So just be regarding understand interim and XXX term what XXX follow addition the for question the have your that find timing XXXX the update in the surprising? updates an you extension? second And the different So of and then appreciated. to up on the

what guidance. the more case seasonality up, you. QX But expect quarter-to-quarter? or QX mention is quarter-over-quarter growth your we as potential seasonal steady we do growth Thank think As and base in implied about potential dynamics, we exit QX, assumptions then we in have? as downward strong follow we did the Should you a

side guess benefits plus our composition don't get matter know on extension work the work Hatch-Waxman the first and we We let's think through the product, extension Okay, out every of take call why the end in the the of of approval the I couple we pediatric equation? year. you start through any do file patent I and course as their terms of would 'XX, a term to, of it, right? that have product patent to months for into XXXX, of

then scope challenged, data and filed and To the when quite a bit And okay, significantly, between, merits of use, it's can't it and and that in some they're these comfortable is, patents a those. should for XXX in It good trials, first, the more original when patent the that XXX extension patents? there, Remember, and but we someone investors annually. degree formality, little first you to specifically adds something address each recently Hatch-Waxman that question. at trials. into we I submitted get some the the would XXX two Well, difference in away, response the our exact et XXX doesn't the But formality. from have go get comes the I once it a second, had of to what that AURORA it's you do refined AURORA a refines and most the patent. language issued be this extension, are But what's thinking to patent we AURORA about So the year number differentiation XXX with XXX, patent. look the want XXX feel a around in. combination. term And of the the adds don't it benefits that further call patent how cetera, the it method somewhat still think nephritis you if is formality. is XXX to predict we data. narrows of does issued those a It's lupus filed And new of represents

and So I more additive think patent to it creates refined patent, it's a XXX. a tighter

Lastly has we of the just the I been production. to production on is XXXX of in the of our guess at focus give question don't but our what years say revenue worth I area two quarterly one guidance, pattern sales would look PSF and

next said, offices? commercially. have to and less all But the that we're it being driven Was seen there's need years, two any fronts COVID to we dynamics patients vacation because going it's just level year believe; hard to to metrics As was continue understand, it drive if caution, gone. one COVID more does. we visiting we've We year kind many that of of show being

cauterize on annual we to So if sales you're piece. to caution, it if the one level I previous think number, because given pertains to guidance there's our of it's just look back looking quarterly haven't guidance. that as one And historically I year's annual would

very Thank helpful. you. Okay,

you. Thank

ahead, our question Please Oppenheimer. Justin. from from And next go Kim comes Justin

really sort our think little -- would about end, like strength sort just and color this you the how of in that what need we under about more thanks based the persist to we of and what quarters for forming just business accounting guidance, of you morning, first midpoint of space in any coming we've terms quarter happen reach low and the Good seen the But need And think can such. business on there talk bit fundamentally a see It's sort end, Hi. great questions. seasonality just taking midpoint, the LUPKYNIS. to as for high the the updated of see about the maybe to to for in guidance? calculations over for

for need too we basically be I it to break at starts. we weeks on getting start just a at out continue queue you asked it's where you think give don't but patient And next, be simplistic Yes. of if were Justin, new patients that we [indiscernible] the overly that it QX. here, of XXX don't the little way, less look don't that for you to day in one Without we this our short than to if quarter, That's about look were forms couple see per want assume or if this reported. which I to we numeric range, I in patients' because actually the ask first but

So start the patient who progression And to this for accelerate. is the hit year our the forms. on of I know, funnel. start we continued top not of have patient the critical numbers still to as starts see the business. forms long-term patients' business most we and want can end new think That's But health model this

We the time, caution, But the year. of are need see the a by seeing. incredibly at that to we're encouraged numbers we throughout level continue to same

is through second piece they go prescriptions, go up summer not patients their that meds. as off on visit patients that to are And drugs, we the pick The their months, change. And make they not sure that on we as retained vacation the need take they or decide to doctor, et need does number to cetera.

of the simple impact. I gives the a range guidance, think some of throughout to upside able to continuing would end being more growth that rest The the quarter-on-quarter midpoint our consistently think is around think about of to you year. it somewhere be if probably hold lower our the our year. of way probably the summer guidance about as is of range is throughout see own our the range And

is stick hockey wrong growth it. the we've think a little seen XQ. stick of -- But in XQ, historically way a bit I to we've While shown explain hockey

in I be of would here we not look half the will think not the business, but as be I at it. that extreme it would about peg all year. consistent I back the

need I order market, quarter-over-quarter. to need consistent guidance. think We we to to high to continue continue end think see to see growth the our I of that in get

just persistent And maybe Okay, great. one the on numbers.

Just number, on cutoff impact on influences the months if year-end XX or seasonality? impact being there's point, wondering if granularity just number, relates there? months XX any based you how that any for the you that that there's the Do as summer or sort of think it the start to calculate cutoff any

that ensure in insurance cetera. amount help good effort unnecessary lapses that patients due is think they've in lesson getting got from to And therapy help changeovers, into we I Well, that discontinuations once their education the get and et opt year-end plan appropriately don't and/or in put learned to to we of us. can process a QX

not drugs But there's most don't time, do that lock cases being or about able we -- says patients after don't I plan to down therapy. XX good to continue there's can been plans only therapy insurance end, us get an only months patients XX and to of months. stay So driver ensure have in on that over think pretty year that. through We've

and aggregate falling there. seasonality. are diagnoses visits, we know have see do measures in office those slowed many that patients would frequently our business a we at off I we terms don't of of that little more months. say that forms start predictive new the Some know patients annually look that that We bit have in

we cautious of And why revenue. course there. that's that So remain impacts

give And last one XX or The a I they're I and right? months, little quarterly time move that call think around by, we reported could would a last months to this reported was the noted XX%. caution XX% months it just it's call, shown XX is And out note XX%. number of bit. persistency XX as small ends, XX-month and we've numbers

time. we're Xmarketplace is So there I out learning as the drug in think the over

Great. Thanks questions and for the taking congrats.

comes ahead, go Please from from And Ed next H.C. question our Wainwright. Ed. Thank Arce you.

my Thanks print. Great. let me taking questions. quarter solid on add my congrats in for And a

you've you've as highs. hitting really quarter, terms the metrics ascertain if can this anything you year. making in is in specifically last began you're those firstly, several of that discuss so are qualitative with So to have now ask an November I'm to that but the is seen, trying of know wanted December just around that think you've numbers, there in commercial mentioned, through and efforts of all-time drivers again, what far gone really particular impact. I And you

aspects initiatives initiations to campaign. and mentioned newer that you You I'm think commercial particularly there's recently helping? excuse particular just or me, specific in initiatives, wondering Get the Uncomfortable if are

others. anymore. we're get get that And tougher are meet our locked that in affects still fact We as than an us, on that more. access. not Thanks, not is many companies that talked some run from end obviously there, But locally. seems are We up at We collectively. I and There the down be an to you right? houses. locked think the our COVID to, it's down we that day, everything thing I would and it's the which wouldn't of business to action behind we're opened not obvious how Ed. -- has the collective point Yes, I together more say first due commercial universal, the because organization to out centers

that's true too. I in think institutions the

So one. COVID is

two to campaign, to that One surged our business get matter efforts in that and deciles campaign. The focused while is messaging six the have disease our recent from worked year most into of take population, had to urge “pee community more represent last treatment seriously, the focused we've we our by we're getting with Ed, differentiated for we've that the the now decile the mentioned urinalysis the right longer organizations we've consistent have And aggressively X a the sponsor our critical. And marketplace to physicians of because product. lies for the that getting campaign, people then always lives campaign, advocacy emphasizes months who product somewhere be most, in data regular efforts XX trying and terms to evidenced very of patient cup” clearly second education the Braxton to, and simply, Get on and point broad-based move that move patient the in this the who is representative term to message there is deliver with advocates with Toni and the in high someone to campaign, support them put we calls been XX% matter efforts trialing we've had really trial about and when we're in active And what identifies are we a X a on now our we from the around in and category, in to there, adoption a of with around would lupus, the this treated. I to to AURORA of launch Uncomfortable lastly, and a think as person with is working the consumer launch study. direct and recent patient get diagnosed are that a a out extension strong XX

of it's think all those combination I factors. a So

to show on And fruit. think them, it's that have starting focus We add doing. on to more, really we're efforts the to I pour continue gasoline

aim And to that's do. continue we have solid produce quarters. to to what We

Great.

that And in the so that, care to follow you how flat frankly, of this the effects fourth couple of from quarter last in years. And sort it up down the as driver a significantly. to year mitigating expecting I is up about of was reset talked continuity seen pretty we've new quarter, big a was the for and

also I'm around So if and wondering efforts Thank qualitatively helpful? that those commentary any mitigate applied seasonality to to could the be summer would be you.

Yes.

use to one how say a about caution even always were may So any because that asked say looking use product still specialty think January of caution like predict. product it's you company tough February about a us, January has should February, transitions, insurance if these thinking I specialty and that would look I when how any about would general still we to at and factors due and business

in I that great trying think we did a manage transition. to job

is our to support bore down I this Ed, can directly and our our on quarter. are acutely fruits a all next three people to and patients our group, field managers tell the case think everything I at the backend of doing for the you nurse from summertime, we're over four looking we that in with months. and patient were focused out in working effort offices intense support put labor and

a plan. So have we

question it of it We seen guidance, the back us, if Alliance the challenges, well how is through And see support go patient identification have think upside that you I including to and for that encompasses we've run Aurinia to support we'd Anyway, all the of end around plan we plays guidance the pretty as set to works bespoke backend the clear lower out some areas out. to get through ranges rep, historically and a how that's and group, we're the we have and education. then if support plays into tactical patient which of office group of on it our range. that probably support,

can in continuing for marketing post But the about Joe and of Thank Peter. quarter obviously expect spend, still you Thanks, specifically if just and last that in, the what is expand we question, All One you probably. I efforts. commercialization And much right. it may used how that is remaining? much. cash to sneak spoke requirement more the so

Yes.

a we pediatric think ongoing. have have few The VOCAL we is most So as study, I being one, probably the know, that studies largest.

fall how time. as sort aged in especially Ed, young XX-year-old XX take comes of or takes execute that in And of areas majority middle that is I patients in women think pediatric know, it are category, it down to, and women, the to long on finding most to the studies, trial. area the the will population where pediatric

you as be pediatrics, protracted. on the think about commitment think I So it'll

on things and the that cetera, is interaction registry drug-on-drug the The we're like working other study. et

the DDI we'll study, I time. over monitor think continue to

as other any and then ongoing. commercially somewhat, as And out relevant got that's relevant pediatric tail think like not we and/or that Phase studies, the long a probably put investigator-initiated on I from be Xs study. registry but clinically data it intend will the initiatives, to

should So not specific being but ongoing I'm them probably think I next for I not couple know but increments, in about six-month here, years. of they'll you the be think

Thanks, Very helpful. again.

Thanks, Ed.

question from ahead, Thank next go from David. Martin our Burton. you. Bloom And take Please David we'll

thanks and morning, Good for taking my Yes. questions.

nephrotoxicity force the on change wording the promoting the is results, study beyond been And year? the wondering a to related regarding I'm question to sales the doctors do has that the First you with FDA biopsy label to ask what now. And also data the LUPKYNIS plan feedback?

to answer is question your the So first no.

take ability physician Our has the is new to through our them Obviously, a this the -- data. they clinically sales biopsy them and/or within data. It's force medical But promoting when that group medical if the to affairs not about asks to can data. letter study, that request forward biopsy is our proactively asked a label. not

in makes the naysayers think with challenges receptivity conversations of I clinical him combination think think those think maybe that some three-year data that these And -- think. this necessarily to was -- second I has around a medical affairs data differentiated eGFR accrue positive. three-year product, story. I tells our group data, through is and so don't quite your And many far, CNIs been I This This, the which question of XX-month to positive. And shows biopsy eGFR is in

Label.

But I is NDA. answer short want Yes, to were done a studies that expectation not to the right supplemental supplemental here. yes. were set These enhance the

and enhancing to conversation, these we, owe their hope -- FDA. be data our a extension the both label. groupings drug to would to for the and the way that good the AURORA into they're are they study through of And that think biopsy make physician So important the -- find first, into because understanding their way understand we study

of the be something will that I impact think it's think indication reach will it a to statement the drug.

question. a second And quick Okay.

down reason PSFs mentioned temporary? You quarter. is daily for it think that versus you first were of a And that? Can

one daily they're basis, per it a say down day. than but is on I And less

it's closely. acutely you X.X So it'd look make the looking doesn't we make tells or whether X game. more It confident. stage at worse. we -- at better, which us at concerned either you real better, it you How it at have We're We probably X of I daily? at guess look this confident how this, this look

I year, were And see month when got fact that think good. last some we a versus the you see new we is softness. to we and it a quarter quarter ends look can begins, -- at always where looking

are yet. if wouldn't to trend and look I I a important at. -- And you're Joe to us going to and data May what call be asking April April So

still I per et trajectory had think off cetera. one first of patient than less shows, look at got the a really May after the that But quarter, what speaking, we to quarter day. in positively first it's we strong

Okay, it. got Thanks.

Thank you. go Securities. ahead, go Schwartz from And to Joseph. next Joseph SVB Please we'll

for for on and you add is my questions Will Hi, all. taking I'll Thank congrats Joe. today, This the for our quarter.

and help you're just the first us, guess you rheumatologists? the Specifically, in has growth the prescriptions prescriptions could this been contextualize I among in for from more more consistent seeing and us So certain nephrologists the quarter? growth centers a bit

significant, I of indicators So I leading call these are more they're of looking that a things, at. say statistically would any couple that we're wouldn't and trends

that new our has of in decile new prescribers seeing deciles more coming So and our out to decile And and from prescriptions that in we're a is top good so working. physicians, coming focus we're more sign focus been on repeat XX. prescribers the docs, addition, group seeing below coming X

would we've top, None marketing up there, we I seeing treating volume metrics. lupus where large an then a that crack, a more. to call More such would say but that because good say that's the centers now. out actually lupus individual on was I I And and sales issue. tactic concentration seen And I break, quarters, in think centers don't academic while opportunity previous the rep our that's limited. quite always this trend have opening patients majority one is are impact has is again, would centers the So it of said focus that been. that we or medical are an And major institutions,

of a to that more think to crack there lot to I do it we'll then need want And some continue think are has about to complexities with that COVID. marketplace. as we

the sale and the physician. than centers process a academic different office here into community moving is quite So complexities around

we've more well. So and prescriptions and that about seen strategically tactically, out we thinking coming that area of are as

and question But was still split said is the you to in the in I've break tell rheumatologist the on middle. rheumatologist the office. generate it's first evenly I would as what past, pretty nephrologists down last Your lupus patients percentage

at very roomed that all that but kidney the how think around sure kidney our now. evenly earlier get physicians prescription buy in how in experts rheumatologist to these disease. our in as of of is they they're story I So because is there, terms can they right or make I drug. need nephrologist And the and And office and data the base message drug the buy look for for penetrating improving acutely the at our understanding our and we metrics the that there, one deeply we understand look I office are

Excellent. Thank last our Sahil. you. from Please And Sahil go ahead, RBC. from question comes Dhingra

the Doug Sahil This from questions. have I some want for you is you Hi. Thank for what provided. just color incremental already Miehm. taking

opportunity. the think not I in you the So an that as and this are past highlighted XX% prescribers, you had prescribers see of repeat

positioning and that data And So competitive the you biopsy has versus have study, improved that Benlysta? given how the long-term you. your renal Thank has evolved? also that study

majority seen said more on because we've So of XX that impact and we're new as prescribers. as repeat would I our to repeat focused the probably seeing increases been decile, and prescribers, just well. X put where on I as both And in that's emphasis mentioned, prescribers we've I

XX% persistency, drug of patients But I across terms have we like categories, with percentage in call time, trend be you yet, rheumatoid XX GI to into I chronic look a from In products wouldn't months you that actually IBD, and diseases, changing I other the areas retain that over the in to total. think seeing more it like quite And XX%. if of the of represented moving we're is whether other MS areas persistency benchmark that other good. think psoriatic indications indications like light rheumatology, the other persistency or specialty versus even arthritis,

and you're increment think quarter, seeing keep periods maintaining I every improvements you So seeing of each But through we three-month that you're we're patients to way. it over continue those the along announced what we'll areas time. those updated in

was question. that Greenleaf, our Mr. last

for forward I to about the today. Have again everybody very We'll a Thank excited first year. look thank We're obviously you to call the quarter great progress the you talk day. in to the Okay. joining us want seen quarter. much. with next we've of

this Ladies your you does you. participation. thank for Thank gentlemen, We teleconference. conclude and today's

at your day. You have may disconnect lines great this a and time,